Cereno Scientific submits Clinical Trial Application (CTA) for first-in-human Phase I study with novel epigenetic HDACi drug candidate CS014
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced the submission of a clinical trial application (CTA) to the European Medicines Agency (EMA) for a first-in-human, Phase I study of novel histone deacetylase inhibitor (HDACi) drug candidate CS014.The CTA was submitted for a first in human Phase I study to primarily evaluate the safety and tolerability of CS014 in healthy volunteers. The design is a traditional single ascending and multiple ascending dose study for 1 week. Title of